ReviewEuropean journal of hospital pharmacy : science and practice2017
Review of structured guides for deprescribing.
Review in European journal of hospital pharmacy : science and practice, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- [Deprescribing in DGPPN S3 guidelines-a systematic analysis].Der Nervenarzt · 2025Pooled it
- Generic instruments for drug discontinuation in primary care: A systematic review.British journal of clinical pharmacology · 2020Pooled it
- Effectiveness of Bundled Hyperpolypharmacy Deprescribing Compared With Usual Care Among Older Adults: A Randomized Clinical Trial.JAMA network open · 2023Trial
- Patterns of Benzodiazepines and Hypnotic Drugs Dispensing After Hip Fracture Among Older US Adults Previously on the Drugs.Journal of the American Geriatrics Society · 2025Article
- Education about deprescribing for pre-licensed and licensed healthcare professionals: A scoping review.British journal of clinical pharmacology · 2025Article
- Education about deprescribing for pre-licensed and licensed healthcare professionals: A scoping review.British journal of clinical pharmacology · 2025Article
- Effectiveness of a multidisciplinary team-delivered deprescribing intervention for patients with chronic kidney disease: a protocol for a randomised controlled trial.Journal of pharmaceutical policy and practice · 2025Article
- Defining, identifying and addressing problematic polypharmacy within multimorbidity in primary care: a scoping review.BMJ open · 2024Article
- Current Landscape and Future Directions of Deprescribing and Polypharmacy Practices in Jordan.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2024Review
- Awareness, perspectives and practices of antibiotics deprescribing among physicians in Jordan: a cross-sectional study.Journal of pharmaceutical policy and practice · 2024Article
- Attitude towards deprescribing and its association with frailty and complexity of medication regimen: A survey of older inpatients in a district health board in New Zealand.BMC geriatrics · 2023Article
- Renal Function, Cardiovascular Diseases, Appropriateness of Drug Prescription and Outcomes in Hospitalized Older Patients.Drugs & aging · 2021Observational
- Attitudes to Drug Use in Residential Aged Care Facilities: A Cross-Sectional Survey of Nurses and Care Staff.Drugs & aging · 2021Article
- Therapeutic Futility in Terminal Cancer Patients: A Retrospective and Observational Study.Cureus · 2021Article
- The Double Burden of the COVID-19 Pandemic and Polypharmacy on Geriatric Population - Public Health Implications.Therapeutics and clinical risk management · 2020Review
- Advancing the Science of Deprescribing: A Novel Comprehensive Conceptual Framework.Journal of the American Geriatrics Society · 2019Article
- Medication use in older patients and age-blind approach: narrative literature review (insufficient evidence on the efficacy and safety of drugs in older age, frequent use of PIMs and polypharmacy, and underuse of highly beneficial nonpharmacological strategies).European journal of clinical pharmacology · 2019Review
- Deprescribing in multi-morbid older people with polypharmacy: agreement between STOPPFrail explicit criteria and gold standard deprescribing using 100 standardized clinical cases.European journal of clinical pharmacology · 2019Article
- Applicability of EU(7)-PIM criteria in cross-national studies in European countries.Therapeutic advances in drug safety · 2019Article
- Using EMR-enabled computerized decision support systems to reduce prescribing of potentially inappropriate medications: a narrative review.Therapeutic advances in drug safety · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Avoiding inappropriate polypharmacy has become increasingly recognised as a safety imperative for older patient care. Deprescribing is an active process of reviewing all medications being used by individual patients that prompts clinicians to consider which medications have unfavourable risk-benefit trade-offs in the context of illness severity, advanced age, multi-morbidity, physical and emotional capacity, life expectancy, care goals and personal preferences. Structured guides to deprescribing include algorithms, flow charts or tables which are patient-directed and aim to guide the clinician through sequential steps in deciding which medications should be targeted for discontinuation. In this narrative review, we describe seven structured deprescribing guides whose stated purpose included the reduction of polypharmacy, their use was not restricted to a single drug or drug class and they had undergone some form of efficacy testing. There was considerable heterogeneity in guide design and content, with some guides constituting little more than a set of principles while others entail detailed processes and sub-steps which addressed multiple determinants of drug appropriateness. Evidence of effectiveness for each guide was limited in that none have been evaluated in randomised controlled trials, that pilot or feasibility studies have involved relatively small patient samples, that intra-rater and inter-rater reliabilities have not been determined and that most have been studied in hospital settings. Which is most useful to clinicians is unknown in the absence of head-to-head comparisons. While most guides have face validity, more research is needed for determining effectiveness and ease of use in routine clinical practice, especially in primary care settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.